株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

C型肝炎 : パイプライン分析

Hepatitis C - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232778
出版日 ページ情報 英文 523 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
C型肝炎 : パイプライン分析 Hepatitis C - Pipeline Review, H2 2016
出版日: 2016年09月30日 ページ情報: 英文 523 Pages
概要

C型肝炎は、肝臓の感染性のウイルス感染で、感染した血との接触で拡大します。症状は穏やかな場合もありますが、長期に渡って長引き、様々な合併症を引き起こすこともあります。 特徴的な症候は腹痛、疲労、熱、黄疸、食欲不振、吐き気、嘔吐などがあります。素因としては透析、臓器移植、輸血などが挙げられます。また、母子感染のリスクもあります。 C型肝炎は、進行した段階で薬物療法または移植で管理します。

当レポートでは、C型肝炎の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • C型肝炎 概要

治療薬の開発

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

治療薬の評価

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8516IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H2 2016, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 33, 19, 1, 56, 41 and 4 respectively for Similarly, the Universities portfolio in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 2, 1, 9 and 24 molecules, respectively for Hepatitis C.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Hepatitis C Overview
  • Therapeutics Development
  • Hepatitis C - Therapeutics under Development by Companies
  • Hepatitis C - Therapeutics under Investigation by Universities/Institutes
  • Hepatitis C - Pipeline Products Glance
  • Hepatitis C - Products under Development by Companies
  • Hepatitis C - Products under Investigation by Universities/Institutes
  • Hepatitis C - Companies Involved in Therapeutics Development
  • Hepatitis C - Therapeutics Assessment
  • Drug Profiles
  • Hepatitis C - Dormant Projects
  • Hepatitis C - Discontinued Products
  • Hepatitis C - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hepatitis C, H2 2016
  • Number of Products under Development for Hepatitis C - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Hepatitis C - Pipeline by 3-V Biosciences, Inc., H2 2016
  • Hepatitis C - Pipeline by AbbVie Inc, H2 2016
  • Hepatitis C - Pipeline by AIMM Therapeutics B.V., H2 2016
  • Hepatitis C - Pipeline by Akshaya Bio Inc., H2 2016
  • Hepatitis C - Pipeline by Amarillo Biosciences, Inc., H2 2016
  • Hepatitis C - Pipeline by Amarna Therapeutics B.V., H2 2016
  • Hepatitis C - Pipeline by ARA Healthcare Pvt. Ltd., H2 2016
  • Hepatitis C - Pipeline by Aviragen Therapeutics, Inc., H2 2016
  • Hepatitis C - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H2 2016
  • Hepatitis C - Pipeline by Benitec Biopharma Limited, H2 2016
  • Hepatitis C - Pipeline by Beta Pharma, Inc., H2 2016
  • Hepatitis C - Pipeline by Biogenomics Limited, H2 2016
  • Hepatitis C - Pipeline by BioLineRx, Ltd., H2 2016
  • Hepatitis C - Pipeline by Bionor Pharma ASA, H2 2016
  • Hepatitis C - Pipeline by Biotest AG, H2 2016
  • Hepatitis C - Pipeline by Biotron Limited, H2 2016
  • Hepatitis C - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Hepatitis C - Pipeline by Bolder Biotechnology, Inc., H2 2016
  • Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Hepatitis C - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
  • Hepatitis C - Pipeline by Cocrystal Pharma, Inc., H2 2016
  • Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
  • Hepatitis C - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
  • Hepatitis C - Pipeline by DEKK-TEC, Inc., H2 2016
  • Hepatitis C - Pipeline by Delpor, Inc., H2 2016
  • Hepatitis C - Pipeline by Digna Biotech, S.L., H2 2016
  • Hepatitis C - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016
  • Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Hepatitis C - Pipeline by Formune S.L., H2 2016
  • Hepatitis C - Pipeline by Genecode AS, H2 2016
  • Hepatitis C - Pipeline by GeneCure LLC, H2 2016
  • Hepatitis C - Pipeline by Gilead Sciences, Inc., H2 2016
  • Hepatitis C - Pipeline by GinkgoPharma Co. Ltd., H2 2016
  • Hepatitis C - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Hepatitis C - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Hepatitis C - Pipeline by HEC Pharm Co., Ltd., H2 2016
  • Hepatitis C - Pipeline by ImmunoBiology Limited, H2 2016
  • Hepatitis C - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Hepatitis C - Pipeline by Integrated BioTherapeutics, Inc., H2 2016
  • Hepatitis C - Pipeline by JN-International Medical Corporation, H2 2016
  • Hepatitis C - Pipeline by Johnson & Johnson, H2 2016
  • Hepatitis C - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Hepatitis C - Pipeline by Kineta, Inc., H2 2016
  • Hepatitis C - Pipeline by LG Life Science LTD., H2 2016
  • Hepatitis C - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
  • Hepatitis C - Pipeline by Medivir AB, H2 2016
  • Hepatitis C - Pipeline by Merck & Co., Inc., H2 2016
  • Hepatitis C - Pipeline by Microbio Co., Ltd., H2 2016
  • Hepatitis C - Pipeline by Microbiotix, Inc., H2 2016
  • Hepatitis C - Pipeline by MultiCell Technologies, Inc., H2 2016
  • Hepatitis C - Pipeline by NeuroVive Pharmaceutical AB, H2 2016
  • Hepatitis C - Pipeline by Novartis AG, H2 2016
  • Hepatitis C - Pipeline by NovaTarg Therapeutics, Inc, H2 2016
  • Hepatitis C - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Hepatitis C - Pipeline by Pfenex Inc., H2 2016
  • Hepatitis C - Pipeline by Pfizer Inc., H2 2016
  • Hepatitis C - Pipeline by PharmaEssentia Corporation, H2 2016
  • Hepatitis C - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
  • Hepatitis C - Pipeline by Presidio Pharmaceuticals, Inc., H2 2016
  • Hepatitis C - Pipeline by Profectus BioSciences, Inc., H2 2016
  • Hepatitis C - Pipeline by Regulus Therapeutics Inc., H2 2016
  • Hepatitis C - Pipeline by REPLICor Inc., H2 2016
  • Hepatitis C - Pipeline by Rodos BioTarget GmbH, H2 2016
  • Hepatitis C - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016
  • Hepatitis C - Pipeline by SomaGenics, Inc., H2 2016
  • Hepatitis C - Pipeline by Sorrento Therapeutics, Inc., H2 2016
  • Hepatitis C - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016
  • Hepatitis C - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016
  • Hepatitis C - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016
  • Hepatitis C - Pipeline by TGV-Laboratories, H2 2016
  • Hepatitis C - Pipeline by Therapix Biosciences Ltd., H2 2016
  • Hepatitis C - Pipeline by Therapure Biopharma Inc., H2 2016
  • Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H2 2016
  • Hepatitis C - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016
  • Hepatitis C - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016
  • Hepatitis C - Pipeline by Zylacta Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hepatitis C - Dormant Projects, H2 2016
  • Hepatitis C - Dormant Projects (Contd..1), H2 2016
  • Hepatitis C - Dormant Projects (Contd..2), H2 2016
  • Hepatitis C - Dormant Projects (Contd..3), H2 2016
  • Hepatitis C - Dormant Projects (Contd..4), H2 2016
  • Hepatitis C - Dormant Projects (Contd..5), H2 2016
  • Hepatitis C - Dormant Projects (Contd..6), H2 2016
  • Hepatitis C - Dormant Projects (Contd..7), H2 2016
  • Hepatitis C - Dormant Projects (Contd..8), H2 2016
  • Hepatitis C - Dormant Projects (Contd..9), H2 2016
  • Hepatitis C - Dormant Projects (Contd..10), H2 2016
  • Hepatitis C - Dormant Projects (Contd..11), H2 2016
  • Hepatitis C - Dormant Projects (Contd..12), H2 2016
  • Hepatitis C - Dormant Projects (Contd..13), H2 2016
  • Hepatitis C - Dormant Projects (Contd..14), H2 2016
  • Hepatitis C - Dormant Projects (Contd..15), H2 2016
  • Hepatitis C - Dormant Projects (Contd..16), H2 2016
  • Hepatitis C - Dormant Projects (Contd..17), H2 2016
  • Hepatitis C - Dormant Projects (Contd..18), H2 2016
  • Hepatitis C - Dormant Projects (Contd..19), H2 2016
  • Hepatitis C - Dormant Projects (Contd..20), H2 2016
  • Hepatitis C - Dormant Projects (Contd..21), H2 2016
  • Hepatitis C - Dormant Projects (Contd..22), H2 2016
  • Hepatitis C - Dormant Projects (Contd..23), H2 2016
  • Hepatitis C - Dormant Projects (Contd..24), H2 2016
  • Hepatitis C - Dormant Projects (Contd..25), H2 2016
  • Hepatitis C - Dormant Projects (Contd..26), H2 2016
  • Hepatitis C - Dormant Projects (Contd..27), H2 2016
  • Hepatitis C - Discontinued Products, H2 2016
  • Hepatitis C - Discontinued Products (Contd..1), H2 2016
  • Hepatitis C - Discontinued Products (Contd..2), H2 2016
  • Hepatitis C - Discontinued Products (Contd..3), H2 2016
  • Hepatitis C - Discontinued Products (Contd..4), H2 2016
  • Hepatitis C - Discontinued Products (Contd..5), H2 2016
  • Hepatitis C - Discontinued Products (Contd..6), H2 2016
  • Hepatitis C - Discontinued Products (Contd..7), H2 2016

List of Figures

  • Number of Products under Development for Hepatitis C, H2 2016
  • Number of Products under Development for Hepatitis C - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top